Glossary
Acronym | Definition | placeholder | placeholder |
---|---|---|---|
AI | Artificial intelligence | placeholder |
placeholder |
AIDS | Acquired immunodeficiency syndrome | placeholder |
placeholder |
AMR | Antimicrobial resistance | placeholder |
placeholder |
ARV | Antiretroviral | placeholder |
placeholder |
BARDA | Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services | placeholder |
placeholder |
CDC | Centers for Disease Control and Prevention | placeholder |
placeholder |
DEI | Diversity, equity and inclusion | placeholder |
placeholder |
DR-TB | Drug-resistant tuberculosis | placeholder |
placeholder |
ECDC | European Centre for Disease Prevention and Control | placeholder |
placeholder |
EH&S | Environmental Health & Safety | placeholder |
placeholder |
EMA | European Medicines Agency | placeholder |
placeholder |
EMEA | Europe, Middle East and Africa | placeholder |
placeholder |
EML | WHO Model List of Essential Medicines | placeholder |
placeholder |
ESG | Environmental, social and governance | placeholder |
placeholder |
EUA | Emergency Use Authorization | placeholder |
placeholder |
EUL | Emergency Use Listing |
placeholder |
placeholder |
ExPEC | Extraintestinal pathogenic Escherichia coli | placeholder |
placeholder |
FDA | U.S. Food and Drug Administration | placeholder |
placeholder |
GCI | Global Community Impact | placeholder |
placeholder |
GBP | Global Brand Protection | placeholder |
placeholder |
GHG | Greenhouse gas or gases | placeholder |
placeholder |
GPH | Global Public Health | placeholder |
placeholder |
HCP | Healthcare professional | placeholder |
placeholder |
HIV | Human immunodeficiency virus | placeholder |
placeholder |
IP | Intellectual Property | placeholder |
placeholder |
JJBC | Johnson & Johnson Bioethics Committee | placeholder |
placeholder |
JJDC | Johnson & Johnson Innovation—JJDC, Inc. | placeholder |
placeholder |
J&J MedTech | Johnson & Johnson MedTech | placeholder |
placeholder |
JLABS | Johnson & Johnson Innovation—JLABS | placeholder |
placeholder |
LAI | Long-acting injectable | placeholder |
placeholder |
LMICs | Low- and middle-income countries | placeholder |
placeholder |
MDR-TB | Multidrug-resistant tuberculosis | placeholder |
placeholder |
NGO | Non-governmental organization | placeholder |
placeholder |
NIH | National Institutes of Health | placeholder |
placeholder |
OCMO | The Johnson & Johnson Office of the Chief Medical Officer | placeholder |
placeholder |
PAH | Pulmonary arterial hypertension | placeholder |
placeholder |
PPE | Personal protective equipment | placeholder |
placeholder |
PTA | Priority Topics Assessment | placeholder |
placeholder |
RLS | Resource-limited settings | placeholder |
placeholder |
RNA | Ribonucleic acid | placeholder |
placeholder |
RSV | Respiratory syncytial virus | placeholder |
placeholder |
RWD | Real-world data | placeholder |
placeholder |
SDG | Sustainable Development Goal (of the United Nations) | placeholder |
placeholder |
SEC | U.S. Securities and Exchange Commission | placeholder |
placeholder |
SSP | Supplier Sustainability Program | placeholder |
placeholder |
STEM | Science, Technology, Engineering, and Mathematics | placeholder |
placeholder |
STH | Soil-transmitted helminthiasis (or intestinal parasites) |
placeholder |
placeholder |
TB | Tuberculosis | placeholder |
placeholder |
VR | Virtual reality | placeholder |
placeholder |
WHO | World Health Organization | placeholder |
placeholder |